IN BRIEF: Diurnal gets another patent for adrenal insufficiency asset

Diurnal Group PLC - Cardiff, Wales-based pharmaceutical company focused on hormonal diseases - ...

Alliance News 23 April, 2021 | 12:56PM
Email Form Facebook Twitter LinkedIn RSS

Diurnal Group PLC - Cardiff, Wales-based pharmaceutical company focused on hormonal diseases - Gets second patent for Alkindi from European Patent Office. Alkindi is a treatment for adrenal insufficiency, when the body's glands do not produce enough cortisol. "The patent provides in-market European protection until 2034 in all designated states of the European Patent Convention. The equivalent patents from the same family are already granted in the UK, Japan, Australia, Israel, South Africa, South Korea, China, India, Russia and the US," Diurnal says.

Current stock price: 72.00 pence, up 5.1% on Friday afternoon

Year-to-date change: up 26%

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Diurnal Group PLC 59.60 GBX -2.30 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.